Ionis Pharmaceuticals Inc (IONS) - Total Assets
Based on the latest financial reports, Ionis Pharmaceuticals Inc (IONS) holds total assets worth $3.03 Billion USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore IONS long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
Ionis Pharmaceuticals Inc - Total Assets Trend (1990–2024)
This chart illustrates how Ionis Pharmaceuticals Inc's total assets have evolved over time, based on quarterly financial data. Check asset resilience ratio of Ionis Pharmaceuticals Inc to evaluate the company's liquid asset resilience ratio.
Ionis Pharmaceuticals Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Ionis Pharmaceuticals Inc's total assets of $3.03 Billion consist of 87.2% current assets and 12.8% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 8.1% |
| Accounts Receivable | $92.19 Million | 3.1% |
| Inventory | $12.51 Million | 0.4% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (1990–2024)
This chart illustrates how Ionis Pharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Ionis Pharmaceuticals Inc (IONS) market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Ionis Pharmaceuticals Inc's current assets represent 87.2% of total assets in 2024, an increase from 44.2% in 1990.
- Cash Position: Cash and equivalents constituted 8.1% of total assets in 2024, down from 41.9% in 1990.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 2.0% in 1990.
- Asset Diversification: The largest asset category is accounts receivable at 3.1% of total assets.
Ionis Pharmaceuticals Inc Competitors by Total Assets
Key competitors of Ionis Pharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Royalty Pharma Plc
NASDAQ:RPRX
|
USA | $19.82 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Inhibrx Biosciences, Inc.
NASDAQ:INBX
|
USA | $146.48 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.23 Billion |
|
Hyundai Bioscience Co. Ltd
KQ:048410
|
Korea | ₩130.74 Billion |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
|
China | CN¥772.57 Million |
|
Lifecome Biochemistry Co Ltd
SHE:002868
|
China | CN¥773.72 Million |
Ionis Pharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.79 | 8.91 | 7.34 |
| Quick Ratio | 2.78 | 8.82 | 7.27 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $1.62 Billion | $2.41 Billion | $1.84 Billion |
Ionis Pharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between Ionis Pharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 22.09 |
| Latest Market Cap to Assets Ratio | 4.12 |
| Asset Growth Rate (YoY) | 0.5% |
| Total Assets | $3.00 Billion |
| Market Capitalization | $12.39 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Ionis Pharmaceuticals Inc's assets at a significant premium (4.12x), suggesting investors see substantial growth potential or unique competitive advantages.
Positive Asset Growth: Ionis Pharmaceuticals Inc's assets grew by 0.5% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Ionis Pharmaceuticals Inc (1990–2024)
The table below shows the annual total assets of Ionis Pharmaceuticals Inc from 1990 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $3.00 Billion | +0.45% |
| 2023-12-31 | $2.99 Billion | +18.00% |
| 2022-12-31 | $2.53 Billion | -2.99% |
| 2021-12-31 | $2.61 Billion | +9.29% |
| 2020-12-31 | $2.39 Billion | -26.07% |
| 2019-12-31 | $3.23 Billion | +21.19% |
| 2018-12-31 | $2.67 Billion | +101.80% |
| 2017-12-31 | $1.32 Billion | +44.88% |
| 2016-12-31 | $912.47 Million | -4.56% |
| 2015-12-31 | $956.11 Million | +0.03% |
| 2014-12-31 | $955.81 Million | +12.83% |
| 2013-12-31 | $847.16 Million | +55.25% |
| 2012-12-31 | $545.69 Million | +12.54% |
| 2011-12-31 | $484.89 Million | -11.91% |
| 2010-12-31 | $550.48 Million | -16.24% |
| 2009-12-31 | $657.18 Million | +14.46% |
| 2008-12-31 | $574.15 Million | +121.80% |
| 2007-12-31 | $258.86 Million | +1.15% |
| 2006-12-31 | $255.91 Million | +53.82% |
| 2005-12-31 | $166.37 Million | -20.18% |
| 2004-12-31 | $208.43 Million | -37.77% |
| 2003-12-31 | $334.94 Million | -23.65% |
| 2002-12-31 | $438.68 Million | +5.18% |
| 2001-12-31 | $417.06 Million | +127.58% |
| 2000-12-31 | $183.26 Million | +77.73% |
| 1999-12-31 | $103.11 Million | +7.29% |
| 1998-12-31 | $96.10 Million | -18.49% |
| 1997-12-31 | $117.90 Million | +16.39% |
| 1996-12-31 | $101.30 Million | +1.71% |
| 1995-12-31 | $99.60 Million | +49.55% |
| 1994-12-31 | $66.60 Million | -15.48% |
| 1993-12-31 | $78.80 Million | +41.98% |
| 1992-12-31 | $55.50 Million | -24.59% |
| 1991-12-31 | $73.60 Million | +1611.63% |
| 1990-12-31 | $4.30 Million | -- |
About Ionis Pharmaceuticals Inc
Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pe… Read more